SI2266534T1 - Aerosolizirana kombinacija fosfomicin/tobramicin za zdravljenje cistične fibroze - Google Patents

Aerosolizirana kombinacija fosfomicin/tobramicin za zdravljenje cistične fibroze

Info

Publication number
SI2266534T1
SI2266534T1 SI200531600T SI200531600T SI2266534T1 SI 2266534 T1 SI2266534 T1 SI 2266534T1 SI 200531600 T SI200531600 T SI 200531600T SI 200531600 T SI200531600 T SI 200531600T SI 2266534 T1 SI2266534 T1 SI 2266534T1
Authority
SI
Slovenia
Prior art keywords
treatment
cystic fibrosis
tobramycin combination
fosfomycin
aerosolized
Prior art date
Application number
SI200531600T
Other languages
English (en)
Inventor
William Baker
David Macleod
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of SI2266534T1 publication Critical patent/SI2266534T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
SI200531600T 2004-05-17 2005-05-02 Aerosolizirana kombinacija fosfomicin/tobramicin za zdravljenje cistične fibroze SI2266534T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57173904P 2004-05-17 2004-05-17
US65900505P 2005-03-03 2005-03-03
EP10168285A EP2266534B1 (en) 2004-05-17 2005-05-02 Aerosolized Fosfomycin/Tobramycin combination for the treatment of Cystic Fibrosis

Publications (1)

Publication Number Publication Date
SI2266534T1 true SI2266534T1 (sl) 2012-12-31

Family

ID=35394588

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200531577T SI2316419T1 (sl) 2004-05-17 2005-05-02 Aerosolna kombinacija fosfomicina/tobramicina za zdravljenje bakterijskih respiratornih infekcij
SI200531250T SI1750667T1 (sl) 2004-05-17 2005-05-02 Aerosolne kombinacije fosfomicina/aminoglikozida za zdravljenje bakterijskih respiratornih infekcij
SI200531600T SI2266534T1 (sl) 2004-05-17 2005-05-02 Aerosolizirana kombinacija fosfomicin/tobramicin za zdravljenje cistične fibroze

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI200531577T SI2316419T1 (sl) 2004-05-17 2005-05-02 Aerosolna kombinacija fosfomicina/tobramicina za zdravljenje bakterijskih respiratornih infekcij
SI200531250T SI1750667T1 (sl) 2004-05-17 2005-05-02 Aerosolne kombinacije fosfomicina/aminoglikozida za zdravljenje bakterijskih respiratornih infekcij

Country Status (19)

Country Link
US (4) US7943118B2 (sl)
EP (3) EP1750667B1 (sl)
JP (1) JP4745340B2 (sl)
AR (1) AR048793A1 (sl)
AT (1) ATE493969T1 (sl)
AU (2) AU2005244153B2 (sl)
BR (1) BRPI0509026A (sl)
CA (1) CA2564546C (sl)
CY (3) CY1112004T1 (sl)
DE (1) DE602005025754D1 (sl)
DK (3) DK2266534T3 (sl)
ES (3) ES2358024T3 (sl)
HK (2) HK1151191A1 (sl)
IL (2) IL179277A (sl)
PL (3) PL2266534T3 (sl)
PT (3) PT1750667E (sl)
SI (3) SI2316419T1 (sl)
TW (1) TWI409074B (sl)
WO (1) WO2005110022A2 (sl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1750667E (pt) 2004-05-17 2011-03-11 Corus Pharma Inc Combinação aerossolizada de fosfomicina/aminoglicósido para o tratamento de infecções respiratórias bacterianas
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
ES2666276T3 (es) * 2006-10-11 2018-05-03 Laboratoires Smb Sa Composición farmacéutica antiinfecciosa para inhalación
WO2008071197A1 (en) * 2006-12-11 2008-06-19 Drugrecure Aps Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
EP2349278A1 (en) * 2008-10-21 2011-08-03 Gilead Sciences, Inc. Fosfomycin/tobramycin combinations for the treatment and prevention of ophthalmic, otological and dermatological infections
AU2010324997A1 (en) * 2009-11-24 2012-05-31 Gilead Sciences, Inc. Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease
WO2011087799A1 (en) * 2009-12-22 2011-07-21 Kalobios Pharmaceuticals, Inc. A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
CA2812044A1 (en) * 2010-08-30 2012-03-08 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
WO2012154483A1 (en) * 2011-05-06 2012-11-15 Gilead Sciences, Inc. Dry powder fosfomycin/tobramycin formulation for inhalation
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
MX2014000540A (es) * 2011-07-12 2014-05-01 Cardeas Pharma Corp Formulaciones de combinaciones de amecacina y forsfomicina y metodos y sistemas para el tratamiento de neumonia asociada a ventilacion mecanica (vap) y traqueobronquitis asociada a ventilacion mecanica (vat).
US8826904B2 (en) 2011-07-12 2014-09-09 Cardeas Pharma Corporation Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
EP2567691B1 (en) * 2011-09-12 2014-12-24 Meiji Seika Pharma Co., Ltd. Aqueous compositions comprising arbekacin
MX2016002524A (es) * 2013-08-26 2016-10-26 Cardeas Pharma Corp Formulaciones de aminoglucosidos y fosfomicina en una combinacion que tiene propiedades quimicas mejoradas.
EP3219305A1 (de) 2016-03-16 2017-09-20 Apostolos Georgopoulos Fosfomycin-formulierung zur parenteralen verabreichung

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5750919A (en) 1980-09-16 1982-03-25 Meiji Seika Kaisha Ltd Agent for reducing side effect
JPS58134028A (ja) 1982-02-05 1983-08-10 Meiji Seika Kaisha Ltd アミノ配糖体抗生物質腎毒性の軽減乃至予防剤
GB9103291D0 (en) * 1991-02-15 1991-04-03 Waverley Pharma Ltd Transfer adaptor
US5488038A (en) * 1992-11-27 1996-01-30 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Dibekacin derivatives and arbekacin derivatives active against resistant bacteria
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
JPH09183730A (ja) 1995-05-10 1997-07-15 Meiji Seika Kaisha Ltd ホスホマイシン鏡像異性体を含んでなる医薬
US6083922A (en) * 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
WO1999017782A1 (fr) * 1997-10-03 1999-04-15 Meiji Seika Kaisha Ltd. Composition pour le traitement du diabete et procede de traitement du diabete
BR9916296A (pt) * 1998-12-17 2004-06-29 Pathogenesis Corp Método para tratamento de bronquite crÈnica severa (bronquiectase) com um antibiótico em forma de aerossol
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
NZ523693A (en) 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
AU2002258563A1 (en) 2001-03-19 2002-10-03 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations for sustained release
JP2004534763A (ja) * 2001-05-18 2004-11-18 カイロン コーポレイション アミノグリコシド抗生物質の吸入投与のための方法および単位用量処方物
TR200401980T4 (tr) * 2001-07-02 2004-09-21 Chiesi Farmaceutici S.P.A. Aerosol olarak uygulama için en uygun hale getirilmiş tobramisin formülasyonu
US20040247628A1 (en) 2001-10-24 2004-12-09 Frank-Christophe Lintz Kit for the preparation of a pharmaceutical composition
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
US7452524B2 (en) * 2004-01-27 2008-11-18 Gilead Sciences, Inc. Method for improvement of tolerance for therapeutically effective agents delivered by inhalation
PT1750667E (pt) 2004-05-17 2011-03-11 Corus Pharma Inc Combinação aerossolizada de fosfomicina/aminoglicósido para o tratamento de infecções respiratórias bacterianas
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
ES2594368T3 (es) 2005-12-08 2016-12-19 Insmed Incorporated Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
WO2008071197A1 (en) 2006-12-11 2008-06-19 Drugrecure Aps Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
US20090054374A1 (en) 2007-02-28 2009-02-26 Paringenix, Inc. Methods of treating acute exacerbations of chronic obstructive pulmonary disease
NZ592685A (en) 2008-10-23 2013-04-26 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
CA2742042A1 (en) 2008-10-23 2010-04-29 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2010324997A1 (en) 2009-11-24 2012-05-31 Gilead Sciences, Inc. Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
PT1750667E (pt) 2011-03-11
EP1750667A2 (en) 2007-02-14
CY1113283T1 (el) 2016-04-13
EP2266534B1 (en) 2012-09-26
US20070218013A1 (en) 2007-09-20
ES2388420T3 (es) 2012-10-15
US20110189103A1 (en) 2011-08-04
PT2266534E (pt) 2012-10-09
DK1750667T3 (da) 2011-04-26
AU2009243536B2 (en) 2012-03-22
PL2316419T3 (pl) 2012-12-31
ES2392389T3 (es) 2012-12-10
JP4745340B2 (ja) 2011-08-10
EP2316419A1 (en) 2011-05-04
AU2009243536A1 (en) 2009-12-24
DK2266534T3 (da) 2013-01-14
US7943118B2 (en) 2011-05-17
EP2266534A1 (en) 2010-12-29
EP1750667B1 (en) 2011-01-05
IL179277A (en) 2013-04-30
TW200608983A (en) 2006-03-16
PT2316419E (pt) 2012-10-22
US20130071442A1 (en) 2013-03-21
ES2358024T3 (es) 2011-05-04
EP1750667A4 (en) 2007-07-11
SI2316419T1 (sl) 2012-10-30
WO2005110022A2 (en) 2005-11-24
DK2316419T3 (da) 2012-10-22
PL1750667T3 (pl) 2011-06-30
HK1151191A1 (en) 2012-01-27
EP2316419B1 (en) 2012-07-11
AR048793A1 (es) 2006-05-24
CA2564546A1 (en) 2005-11-24
TWI409074B (zh) 2013-09-21
SI1750667T1 (sl) 2011-04-29
US8361444B2 (en) 2013-01-29
US8409549B2 (en) 2013-04-02
HK1157637A1 (en) 2012-07-06
AU2005244153B2 (en) 2009-10-29
CY1113319T1 (el) 2016-04-13
AU2005244153A1 (en) 2005-11-24
ATE493969T1 (de) 2011-01-15
CY1112004T1 (el) 2015-11-04
PL2266534T3 (pl) 2013-02-28
US8980226B2 (en) 2015-03-17
IL225529A (en) 2014-08-31
WO2005110022A3 (en) 2006-04-06
BRPI0509026A (pt) 2007-09-18
IL179277A0 (en) 2007-05-15
IL225529A0 (en) 2013-06-27
DE602005025754D1 (de) 2011-02-17
JP2007538075A (ja) 2007-12-27
CA2564546C (en) 2013-02-26
US20110117030A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
HK1151191A1 (en) Aerosolized fosfomycin/tobramycin combination for the treatment of cystic fibrosis
HK1143315A1 (en) Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
EG24526A (en) Atomizer for distributing liquids for medical purposes
TWI369987B (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
ZA200902805B (en) Motion-sensing air freshener of the spray type
PL1931478T3 (pl) Dysza rozpylająca dla dwóch płynów
ZA200803440B (en) Compounds for the treatment of metabolic disorders
SG122049A1 (en) Plasma spray apparatus
EP1954356A4 (en) Spray nozzles
PT1530466E (pt) Utilização de nintedanib para o tratamento de fibrose pulmonar
EP1819639A4 (en) PROCESS FOR TREATING NEBULIZATION
EP1908527A4 (en) ELECTROSTATIC SPRAYER
EP1905516A4 (en) ELECTROSTATIC SPRAYER
IL189171A (en) Use of Fat-Glycosaminoglycan or Fat-Carboxymethyl Cellulose Couplings for the Treatment of Cystic Fibrosis Treatment
EP1986952A4 (en) METHOD FOR THE TREATMENT OF MUCOVISCIDOSIS
ZA200704391B (en) Treatment and control of severe infections including cystic fibrosis
EP1964615A4 (en) ELECTROSTATIC ATOMIZER
PT1945243E (pt) Utilização da calcitonina para o tratamento da ar
EP1928504A4 (en) GENE THERAPY IN THE LIVER
GB0514000D0 (en) Electrostatic atomiser
ZA200704977B (en) Nebulizer formulation
EP1667518A4 (en) TREATMENT OF MUCOVISCIDOSIS WITH GAMMA TOCOPHEROL
AU2006274690A8 (en) Antitumoral compounds
GB0203808D0 (en) The treatment of cystic fibrosis
PL378089A1 (pl) Sposób mycia nebulizera mikrokapilarnego